perampanel (Fycompa)
Jump to navigation
Jump to search
Introduction
DEA class 3.
Indications
- adjunctive treatment of partial seizures for patients >= 12 years of age
Dosage
Adverse effects
- boxed warning of neuropsychiatric effets
- dizziness
- drowsiness
- fatigue
- falls
- upper respiratory tract infection
- weight increase
- vertigo
- ataxia or other gait disturbance
- balance disorder
- blurred vision
- dysarthria
- asthenia
- hypersomnia
Laboratory
Mechanism of action
More general terms
References
- ↑ FDA News Release, Oct. 22, 2012 FDA approves Fycompa to treat seizures http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325038.htm
- ↑ U.S. FDA APPROVES EISAI'S AMPA RECEPTOR ANTAGONIST FYCOMPA<TM> (PERAMPANEL) AS ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 12 AND OLDER http://www.eisai.com/news/news201274.html
- ↑ Prescriber's Letter 21(8): 2014 No Detail Document. (subscription needed) http://www.prescribersletter.com